This article is more than 5 years old. Information may no longer be current.
VIDEO: Comparison of stents in long peripheral lesions reveals difference in fracture rates
Click Here to Manage Email Alerts
LAS VEGAS — In this video exclusive, John R. Laird, MD, presents 2-year results from the TIGRIS randomized trial of a novel nitinol stent for long lesions in the superficial femoral and proximal popliteal arteries.
The head-to-head, real-world, long-lesion trial compared the novel Tigris nitinol stent (W.L. Gore & Associates) with the LifeStent (Bard Peripheral Vascular).
With regard to the primary endpoint of primary patency, there was no significant difference between the two stents at 12 months or at 24 months, according to Laird, who is professor of medicine and medical director of the vascular center at University of California-Davis Medical Center, Sacramento, California.
“One of the most important findings from the trial ... was a remarkably high rate of stent fracture in the LifeStent arm,” Laird said. No stent fractures were observed in the Tigris rom but the stent fracture rate was 27.1% in the LifeStent arm.
“Overall, this was a unique trial because of the complexity of the lesions that were being treated,” he said.